Search
Ferrous bisglycinate
go.drugbank.com/drugs/DB11210ApprovedFerrous bisglycinate is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional . It is found in foods for food e...
Mixtures: FeRiva FACaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigational[A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963] … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Adrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnAdrafinil does not currently have FDA approval and is thus unregulated in the United States. … It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.
Technetium Tc-99m pyrophosphate
go.drugbank.com/drugs/DB09165ApprovedA radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in dif...
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab].
Midazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[F2977] This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. … [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults.
Zinc chloride
go.drugbank.com/drugs/DB14533Approved[L14189] Zinc chloride was granted FDA approval before 26 June 1986.[L14189]
Fenofibrate
go.drugbank.com/drugs/DB01039ApprovedInvestigational[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]